Navigation Links
Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments
Date:11/9/2009

ptember 30, ------------------ ----------------- 2009 2008 2009 2008 ---- ---- ---- ---- (unaudited) (unaudited) Revenues Manufacturing services $1,737 $1,442 $4,663 $5,461 Collaborative agreements 882 415 3,042 1,650 --- --- ----- ----- Total revenues 2,619 1,857 7,705 7,111 Operating Expenses Cost of manufacturing services 1,705 1,743 4,702 6,362 Research and development 22,147 47,475 88,972 151,050 General and administrative 5,423 5,924 18,725 21,938 Restructuring charges - - 3,324 - Amortization of acquired technology & other intangibles 582 580 1,721 1,748 --- --- ----- ----- Total operating expenses 29,857 55,722 117,444 181,098 Interest and Other Income (Expense) Interest income 75 1,332 291 6,529 Interest expense (7,339) (1,399) (10,991) (4,367) Gain from valuation of derivative liabilities 2,472 - 345 - Warrant settlement expense - (242) - (2,236) Loss on extinguishment of debt (2,479) - (2,479) - Other (326) (1,453) (859) (1,299) ---- ------ ---- ------ Total interest and other expense, net (7,597) (1,762) (13,693) (1,373) ------
'/>"/>
SOURCE Arena Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences
2. Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia
3. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
4. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
5. Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
6. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
7. Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
8. Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis
9. Critical Pharmaceuticals Enter Sustained Release hGH Arena
10. Arena Pharmaceuticals Announces Preliminary Results of Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
11. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... SETAUKET, N.Y. , Jan. 23, 2015  Lixte Biotechnology Holdings, ... where its Phase I trial of Lixte,s lead compound, LB‑100, ... institutions. John S. Kovach , M.D., the ... was planned to be completed at a single site. Accrual ...
(Date:1/23/2015)... Jan. 23, 2015  Mallinckrodt plc (NYSE: MNK ... approved a share repurchase program. The open-ended authorization permits ... Mallinckrodt plc ordinary shares. "Funding additional ... priorities as we continue to pursue a range of ...
(Date:1/22/2015)... , Jan. 22, 2015  ViewRay™, a privately held medical ... an exclusive distributor agreement with ITOCHU Corporation (Tokyo Stock ... system for the treatment of cancer in ... is the world,s first and only MRI-guided radiation therapy ...
Breaking Medicine Technology:Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4ITOCHU Named the Exclusive Distributor for ViewRay's MRI-Guided Radiation Therapy System in Japan 2
... with investigators worldwide to develop new treatments for ... diverse forms of cancer - Plenary ... of patients with early-stage breast cancer, - Four oral sessions to feature ... study in renal cell ...
... Hispanics/Latinos, People ... with Diabetes and Obese Individuals, PARSIPPANY, N.J., ... presented at the American Society of,Hypertension,s Twenty- Third Annual ... powerful combination drug AZOR(TM),(amlodipine and olmesartan medoxomil) safely and ...
Cached Medicine Technology:Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 2Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 3Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 4Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 5Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 6Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 7Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 8Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 9Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 10Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 2Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 3Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 4Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 5Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 6Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 7
(Date:1/22/2015)... A new white paper by The Beryl Institute ... long-term care environment as well as provides recommendations for ... “The Power of Person-Centeredness in Long-Term Care: A View ... patient, resident and family experience in long-term care and ...
(Date:1/22/2015)... 20 years, Dr. David Cruz of Cruz Chiropractic Care ... about every type of injury that can result from car accidents ... years, the team at Doctors on Liens has been ... With the combined breadth of experience between the two, ...
(Date:1/22/2015)... York, NY (PRWEB) January 22, 2015 ... College of Sports Medicine flagship journal Medicine & ... with L-Citrulline before exercise may help reduce gastrointestinal ... exercise. 1 , Participants in the double-blind, ...
(Date:1/22/2015)... IsoComforter, Inc. has introduced the most innovative and ... to treat specific body parts and muscle groups. , ... to use patented cold therapy machine with the innovative IsoTube ... muscle injuries. IsoComforter has become the industry leader in ...
(Date:1/22/2015)... 2015 EBSCO Information Services (EBSCO) ... their relationship in an effort to further promote visibility and ... EBSCO has long made AMA journals available via its subscription ... The JAMA Network. , Long known as both ...
Breaking Medicine News(10 mins):Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4
... Up Call as Lighthouse International and EHE International unveil a ... of New Yorkers will see a new warning sign in ... their vision. The sign, located at 10 Rockefeller Plaza and ... a l03-year-old leader in vision healthcare. It will be on ...
... Over 80 percent of Americans suffer from ... their skin, but their self esteem as well. Many reach ... in cosmetic products in the European Union and the desire ... are taking a hard look at their acne treatments and ...
... session in Orlando, FL will feature strategies and tools that increase ... ... Orlando, FL (Vocus) January 8, 2009 -- Facing unprecedented marketplace disruption ... consumer autonomy in health insurance selection - the retention of individual ...
... NEW ROCHELLE, N.Y., Jan. 8 Natural gas, believed to ... airborne particulate matter when burned in home appliances such as ... the December 2008 issue (Volume 25, Number 10) of ... Mary Ann Liebert, Inc. The paper ...
... and the University of Barcelona have shown that treatment ... pomace, results in a significant inhibition of cell proliferation ... is a novel natural compound and it is able ... colon-cancer cells via the intrinsic mitochondrial pathway. Scientifics suggest ...
... safety advocates to launch congressional campaign to prod all ... 40,000 deaths and $230 billion in economic losses.***Free Webcast ... Conference***WASHINGTON, Jan. 8 The following was issued by ... As state legislatures across the nation gear up for ...
Cached Medicine News:Health News:61 Million Americans are at Risk of Vision Loss and Don't Even Know It 2Health News:61 Million Americans are at Risk of Vision Loss and Don't Even Know It 3Health News:World Health Care Congress and Connextions Health Will Host Leadership Summit to Address Member Retention for Health Insurance Plans 2Health News:World Health Care Congress and Connextions Health Will Host Leadership Summit to Address Member Retention for Health Insurance Plans 3Health News:World Health Care Congress and Connextions Health Will Host Leadership Summit to Address Member Retention for Health Insurance Plans 4Health News:Particulate Emission from Natural Gas Burning Home Appliances Is Assessed in Environmental Engineering Science Journal 2Health News:Each State to Receive Report Card Grading Their Progress in Passing Model Traffic Safety Laws 2
... The BioPlex 2200 system is ... platform that can deliver up to ... will initially include a panel of ... in development are in the areas ...
... and a FAM-labeled probe that is designed to ... gene. In addition, the B. pertussis ASR contains ... an internal control sequence. This ASR requires an ... reporter dyes such as the Cepheid SmartCycler System. ...
... The Stratus CS Analyzer, designed for Acute Care ... your laboratory and near patient setting. It's a ... or D-Dimer results from a whole blood sample ... 3 step process load sample and rotor, ...
... The CritSpin whisper quiet, compact system is ... anywhere fast, accurate and cost effective microhematocrits ... Reader, the CritSpin System offers a range ... complete cell packing - Meets NCCLS standards ...
Medicine Products: